Alissandra L. Hillis

This study identifies BRD2 as a co-targetable vulnerability with PI3K/AKT inhibitors in breast cancer, showing that BRD2 phosphorylation is required for chromatin binding and that targeting BRD2 enhances drug efficacy.

The paper identifies and validates tyrosine phosphorylation sites on metabolic enzymes using parallel phosphoproteomics and metabolomics in MCF10A cells.

This study identifies sex-specific metabolic reprogramming in obesity by analyzing phosphorylation sites on metabolic enzymes and their functional impact.

This study identifies a synergistic effect between AKT inhibitors and pitavastatin in killing triple-negative breast cancer cells by targeting cholesterol trafficking.